Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study

The data from this study show that MM-II has the potential to provide durable pain relief for our patients

Lupin receives approval from USFDA for Brexpiprazole Tablets

Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)

CTSI appoints Harish Trivedi as CEO, South Asia

PHARMAP 2023 to focus on pharmaceutical challenges and strategies

The Congress gathers the whole value chain of the pharmaceutical industry on June, 12-13, 2023 in Switzerland

Caplin receives USFDA approval for Rocuronium Bromide Injection

Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)

Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing

All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking

AI platforms market for healthcare industry to reach $4.3 billion in 2024: GlobalData

Various healthcare companies are already implementing high-tech solutions into existing healthcare systems.

Patritumab Deruxtecan shows better clinical activity in patient with lung and breast cancer

Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session

Janssen announces novel dengue antiviral demonstrates efficacy in pre-clinical data

The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans

Phase 3 data show Deuruxolitinib significantly improve scalp hair regrowth in Alopecia Areata

The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022